MedTrace Logo

IL-13 Blockade and Airway Autoimmunity in Asthma

NCT05564078 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 30

Last updated 2026-01-09

No results posted yet for this study

Summary

It has been observed that certain section of patients having severe to moderate Asthma, do not benefit from oral corticosteroids and IL-5 blocking biologics. There is increasing evidence that Airway auto immunity may be responsible for this poor response to treatment. It has been seen in earlier study done at Nair lab that these patients might benefit from Dupilumab, a biologic blocking IL-13/ IL-4. IL-13/IL-4 are the cytokines responsible for increased inflammation in these Asthmatics. The hypothesis is that blocking IL-13/IL-4 will also reduce the airway auto immunity which can be measured by comparing the auto immune markers in airway at baseline (before starting Dupilumab) and 16 weeks (after 4 months of Dupilumab treatment.

Conditions

  • Airway Auto Immunity in Asthma

Sponsors & Collaborators

Principal Investigators

  • Manali Mukherjee, PHD · McMaster University

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-09-28
Primary Completion
2025-09-17
Completion
2025-09-17

Countries

  • Canada

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05564078 on ClinicalTrials.gov